Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 30,662 |
|
|||||
| News | (1) | ||||||
| Day High | 2.05 | Low High |
|||||
| Day Low | 1.96 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Acurx Pharmaceuticals Inc | ACXP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.02 | 0.99% | 2.05 | 10:35:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.03 | 1.96 | 2.05 | 2.03 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 51 | 30,662 | $ 2.02 | $ 62,022 | - | 1.17 - 8.82 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:35:02 | 75 | $ 2.05 | USD |
Acurx Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 27.4M | 13.77M | - | 0 | -14.58M | -1.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Acurx Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACXP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.90 | 2.17 | 1.80 | 2.06 | 67,104 | 0.15 | 7.89% |
| 1 Month | 2.44 | 2.48 | 1.52 | 1.91 | 84,009 | -0.39 | -15.98% |
| 3 Months | 3.34 | 3.35 | 1.52 | 2.52 | 92,010 | -1.29 | -38.62% |
| 6 Months | 3.96 | 5.70 | 1.52 | 3.69 | 213,138 | -1.91 | -48.23% |
| 1 Year | 3.40 | 8.82 | 1.17 | 3.41 | 273,949 | -1.35 | -39.71% |
| 3 Years | 5.95 | 8.82 | 1.17 | 4.36 | 158,253 | -3.90 | -65.55% |
| 5 Years | 5.95 | 8.82 | 1.17 | 4.36 | 158,253 | -3.90 | -65.55% |
Acurx Pharmaceuticals Description
| Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. |
